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OBJECTIVES Our objective was to determine the effect of a nitric oxide synthase inhibitor, NG-nitro-L-
arginine (L-NNA) on free radical generation and myocardial contractility after ischemia-
reperfusion.
BACKGROUND Cardiotoxic free radicals are generated by ischemia-reperfusion sequences. Nitric oxide reacts
with superoxide radical to form peroxynitrite, which generates additional free radicals. Our
hypothesis was that by inhibiting NO production, free radical formation will be diminished,
which should be cardioprotective.
METHODS We studied 32 dogs. Coronary occlusion-reperfusion (20 min each) sequences were created
by intracoronary balloon angioplasty inflation-deflation. Using electron paramagnetic reso-
nance, we monitored the coronary sinus concentration of ascorbate free radical (Ascz2), a
measure of total oxidative flux. The L-NNA (4.8 mg/kg total) was infused intravenously
during occlusion-reperfusion; control dogs received saline. Immunohistochemical staining
demonstrated the peroxynitration product nitrotyrosine.
RESULTS In the control dogs Ascz2 rose from 3.2 6 SD 0.5 nmol/l to 4.8 6 1.1 nmol/l with
reperfusion, a 50% rise. With L-NNA the Ascz2 rose from 3.2 6 0.9 nmol/l to 4.0 6
1.2 nmol/l, a 25% rise (p , 0.01, L-NNA vs. control). Echocardiographic left ventricular
fractional area shortening (FAS) in the control dogs declined from 38 6 19% (baseline) to
26 6 14% (ischemia), and to 22 6 11% with reperfusion (p , 0.01 vs. baseline). With
L-NNA, FAS declined from 36 6 13% (baseline) to 27 6 12% (ischemia) but then rose to
33 6 14 with reperfusion (p 5 NS vs. baseline). Nitrotyrosine was present in the myocardium
subjected to ischemia-reperfusion, but almost absent in dogs receiving L-NNA. Myocardial
perfusion was not altered by L-NNA.
CONCLUSIONS The NO synthase inhibitors decrease coronary sinus free radical concentration and ameli-
orate myocardial stunning after ischemia-reperfusion. (J Am Coll Cardiol 2001;38:546–54)
© 2001 by the American College of Cardiology
Ischemia-reperfusion injury is thought to be due to the
generation of oxygen-derived free radicals such as the
superoxide and hydroxyl radicals (1–5). Such free radicals
lead to lipid peroxidation, cellular dysfunction and stunning
of myocardium. If free radical generation can be limited
during reperfusion, less myocardial injury and stunning may
occur.
Various metabolic pathways lead to the formation of both
oxygen and nitrogen free radicals. These species include
reactive oxygen species such as O2
z2 (superoxide), HOz
(hydroxyl radical), and LOOz (lipid peroxyl radicals) and
reactive nitrogen species such as nitric oxide (NO) and
nitrogen dioxide. Nitric oxide is synthesized from oxidative
deamination of arginine by nitric oxide synthase (NOS),
forming citrulline. Competitive inhibitors of NOS are
usually derivatives of L-arginine with substitutions on the
nitrogen atom of the guanidino group, such as NG-
monomethyl-L-arginine, NG-nitro-L-arginine methyl ester
(L-NAME) and NG-nitro-L-arginine (L-NNA). These in-
hibitors will decrease the production of nitric oxide (6). If
NOS is active, the resulting formation of NO activates
cyclic guanosine monophosphate (cGMP) synthesis.
Oxidation products of NO, namely nitrite and nitrate, are
released by the hearts of patients undergoing acute myocar-
dial infarction and percutaneous transluminal coronary an-
gioplasty (7). Levels of NO in excess of that required to
activate cell cGMP synthesis combine with reactive oxygen
species, such as superoxide. Nitric oxide rapidly reacts with
superoxide to form peroxynitrite anion in high yield (8–13).
Peroxynitrite decays rapidly once it is protonated to form
peroxynitrous acid, which is unstable and has a half-life of
,1 s. In the presence of oxidative substrates, peroxynitrous
acid-mediated oxidation of the substrate occurs via electron
transfer, leading to the formation of other free radicals. In
the absence of oxidative substrates, nitrate is formed.
The overall aim of this study was to demonstrate that the
L-arginine-NO pathway contributes to free radical genera-
tion, which leads to ischemia-reperfusion injury. To accom-
plish this aim, we proposed a testable hypothesis: by
inhibiting NO production in a closed-chest canine isch-
emia-reperfusion model, peroxynitrite and free radical for-
mation should be diminished. Thus, NO synthase inhibitors
may have cardioprotective effects. We utilized a previously
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developed and validated technique, electron paramagnetic
resonance (EPR) measurements of ascorbate free radicals, a
real-time quantitative marker of free radical generation.
METHODS
Animal preparation. A closed-chest canine model was
used; 32 dogs were studied in total. General anesthesia was
achieved with combination of 400 mg of ketamine and
105 mg of xylazine intramuscularly, followed by 20 mg/kg
of pentobarbital intravenously (IV) for continued sedation
as needed. Ventilation was provided by a volume cycled
respirator after endotracheal intubation; tidal volume, respi-
ratory rate and FiO2 were adjusted according to frequent
blood gas measurements, to maintain physiologic pH (7.35
to 7.45), and PO2 .100 torr.
The left femoral artery and vein were cannulated for
administration of IV medications and blood pressure mon-
itoring. The right carotid artery and jugular vein were
cannulated. Then, under fluoroscopic guidance a 6F USCI
Gensini catheter was placed via the jugular vein into the
right atrium and advanced into the coronary sinus. Again
under fluoroscopic guidance, a balloon dilation catheter (for
coronary occlusion), with a balloon diameter of 2.5 mm and
balloon length of 20 mm, was placed via the carotid artery
into the proximal portion of the left anterior descending
(LAD) coronary artery. A very brief balloon inflation was
done under fluoroscopy, and coronary artery occlusion was
confirmed with angiographic contrast injection.
EPR. The ascorbate free radical (Ascz2) is a resonance-
stabilized tricarbonyl species that is readily formed from the
one-electron oxidation of ascorbate, AscH2. Because of the
low potential of the Ascz2/AscH2 couple, ascorbate is the
terminal small molecule antioxidant (14–16). Nearly every
oxidant, including peroxynitrous acid, that could be present
in a biological system will bring about the one-electron
oxidation of ascorbate (14). Thus, the concentration of
ascorbate free radical, as monitored by EPR, is an excellent
measure of the degree of free radical stress (total oxidative
flux) in chemical, biochemical and biologic systems (17–19).
For this study we used a method we have previously
described in detail (20). A brief description is given here. A
Varian E-4 spectrometer with a TM110 cavity and an
aqueous flat cell was used to monitor Ascz2. The lower end
of the flat cell was connected to a Teflon tubing (OD
0.5 mm), which was connected to a manifold with multiple
ports. The coronary sinus catheter and the femoral artery
catheter were connected to different ports of the manifold.
The upper end of the flat cell was connected to the femoral
vein with a variable-speed infusion pump. Thus, coronary
venous blood was circulated continuously through the spec-
trometer at a determined rate. To scan the arterial blood,
the manifold was switched from coronary sinus to femoral
artery. The blood sample was scanned within 4 s of leaving
the vein or artery.
The EPR instrument settings used to acquire optimum
Ascz2 spectra were as follows: nominal power 5 40 mW;
modulation amplitude 5 0.63 Gauss; time constant 1 s; scan
rate 5 1 Gauss per 24 s. The spectra of Ascz2 (aH 5 1.8
Gauss) is typically a doublet. The peak-to-peak height (in
mm) of the Ascz2 signal was measured and normalized to
full instrument gain. The actual concentration of Ascz2 was
determined from the signal height as previously described
using 3-carboxyproxyl as a standard accounting for satura-
tion effects (15,16). For our experimental conditions, 1 mm
of normalized Ascz2 signal height corresponds to 0.073
nmol/liter Ascz2 in the blood being sampled as the volume
of blood in the EPR flat cell remains constant.
Without ascorbic acid supplementation, a weak Ascz2
signal (about 1 nmol/l) can often be detected in the arterial
blood, but not in the coronary sinus blood. To obtain an
adequate EPR signal, 1 g of 1-ascorbic acid was infused IV
as a bolus, followed by a slow infusion. The Ascz2 signal
could then be obtained from arterial and coronary venous
blood. The Ascz2 concentration varied from animal to
animal; the arterial Ascz2 signal was usually about
14 nmol/l; the venous Ascz2 signal was usually 8 nmol/l.
The negative arterial-venous gradient suggests that the
ascorbate radical is repaired by the nicotinamide adenine
dinucleotide (NAD) system as red blood cells pass through
the myocardium. We maintained a steady-state level of
arterial Ascz2 by adjusting the rate of ascorbic acid infusion
(usually between 3.8 and 15.2 mg/ml); the arterial Ascz2
level was rechecked frequently. Arterial pH was maintained
between 7.35 and 7.45 by respirator adjustments.
Left ventricular function. Left ventricular systolic con-
traction was measured by transthoracic echocardiography by
a Hewlett-Packard (Andover, Massachusetts) Ultrasound
Imaging System. Two-dimensional left ventricular cavity
images in the parasternal short axis view were obtained at
the papillary muscle level at baseline, after 15 min of
coronary occlusion and after 15 min of reperfusion. Left
ventricular end-diastolic and end-systolic areas were deter-
mined by planimetry by an observer blinded as to treatment
group, and the percent area shortening was determined
using the following formula: end-diastolic area minus end-
systolic area divided by end-diastolic area.
Interobserver variability was assessed by having a second
Abbreviations and Acronyms
Ascz2 5 ascorbate free radical
cGmp 5 cyclic guanosine monophosphate
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HOz 5 hydroxyl radical
IV 5 intravenously
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L-NNA 5 NG-nitro-L-arginine
NAD 5 nicotinamide adenine dinucleotide
LOOz2 5 lipid peroxyl radicals
NO 5 nitric oxide [nitrogen monoxite]
NOS 5 nitric oxide synthase
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547JACC Vol. 38, No. 2, 2001 Zhang et al.
August 2001:546–54 Nitric Oxide Synthase Inhibitors, Radicals and Stunning
(independent) observer planimeter 20 randomly selected
images to compare the area determinations to those of the
initial observer. Intraobserver variability was determined by
having the initial observer re-planimeter 17 images 1 month
after the initial determination to compare the two data sets.
Measurement of myocardial blood flow by neutron acti-
vation assay. To investigate the effect of myocardial blood
flow on this study, a new method using stable isotope-
labeled microspheres for the measurement of myocardial
blood flow was employed in 11 dogs (21). Five control dogs
received saline injection and another six dogs received
L-NNA before and during the occlusion-reperfusion se-
quence as above.
To gain access to the left atrium, a thoracotomy was
performed and a catheter was inserted into the left atrium
for injection of microspheres. Two additional catheters were
inserted into the left carotid artery and the right femoral
artery, respectively, to collect reference blood samples.
Three milliliters (’7 3 106) of 15 mm stable isotope-
labeled microspheres (BioPAL, Wellesley Hills, Massachu-
setts) was injected through the left atrial catheter to measure
myocardial blood flow in three conditions: baseline, occlu-
sion and reperfusion. Simultaneously, two reference blood
samples were drawn from carotid and femoral arteries using
a withdrawal pump. The withdrawal rate was set at
2 ml/min, and blood was collected over a 3.5-min interval,
resulting in a 7-ml reference blood collection.
After sacrificing the animal, the heart was removed and
vigorously rinsed with distilled water to remove blood before
being fixed for 48 h in formaldehyde. Two transmural
myocardial tissue samples in each animal were taken from
the area distal to the LAD occlusion (risk region). The
blood samples were rinsed using a sodium-free solution
(sansSaLine, BioPAL, Wellesley Hills, Massachusetts) and
then centrifuged for 1 min at ;2,500 rpm. After discarding
the supernatant, the blood samples and myocardial tissue
were dried in a warming-oven (70°C overnight). The dried
blood and tissue samples were sealed in vials and sent to
BioPAL for neutron activation and measurement of re-
gional myocardial perfusion, as described in detail by Rein-
hardt et al. (21).
Risk area assessment. In 14 dogs the degree of myocar-
dium at risk was determined by direct staining. Five
milliliters of 0.5% Evans blue dye was injected at the
completion of the protocol through the distal tip of the
balloon catheter, after inflation of the balloon. The area that
was stained was the LAD risk area, as the dye was only
distributed in the LAD distribution distal to the balloon
inflation. The heart was removed and the entire left ventri-
cle was weighed, followed by dissection and weighing of the
stained risk area, allowing the percent of myocardium at risk
to be calculated. This was done to show that our results were
not influenced by variations in percent of risk area size
between control and intervention groups.
Protocol. Once stable Ascz2 signals were obtained, a base-
line echocardiogram was done. An initial bolus of L-NNA
(Sigma Chemical, St. Louis, Missouri) 0.2 mg/kg/min IV
was infused for 8 min. After this initial bolus, a maintenance
infusion of 0.08 mg/kg/min IV was continued throughout
40 min of coronary artery occlusion and reperfusion. The
balloon catheter was inflated to a pressure of 120 psi for
20 min. Verification of coronary artery occlusion was mon-
itored by arterial blood pressure decline with occlusion,
electrocardiogram changes and echocardiographic evidence
of wall motion abnormality. After 20 min of occlusion, the
balloon was deflated to accomplish reperfusion. The coro-
nary sinus Ascz2 signal was monitored from the beginning
of occlusion through 15 min of reperfusion. The femoral
artery Ascz2 signal was rechecked to verify Ascz2 signal
stability prior to occlusion, at 15 min of occlusion and at
15 min of reperfusion. Echocardiography was repeated after
15 min of coronary artery occlusion and 15 min of coronary
artery reperfusion. Arterial blood gases were obtained at the
time of coronary artery occlusion, 10 min after occlusion,
and at 5 min of reperfusion. After 20 min of reperfusion, the
balloon catheter was reinflated and Evans blue dye was
injected through the distal tip of the balloon to determine
the coronary risk area. Euthanasia was then achieved by
massive IV barbiturate overdose.
Nitrotyrosine immunohistochemistry. In seven dogs,
myocardium subjected to an occlusion-reperfusion sequence
was prepared for immunohistochemistry using a method we
recently described (22). After the occlusion-reperfusion
experiment was completed the heart was removed and
perfused with 4% formaldehyde buffer (500 ml). Left
ventricular myocardial biopsies were obtained from the risk
area, cut into 2-mm sections, and postfixed for 2 h in
formaldehyde buffer. Tissue sections were subsequently
processed through graded alcohols to paraffin blocks. Sec-
tions (4 mm) were cut from each block, mounted on
Superfrost histology slides (Fisher Scientific, Pittsburgh,
Pennsylvania), and deparaffinized in three changes of xylene
(5 min each) followed by two changes in 100% ethanol.
Endogenous peroxidase activity was blocked with a 30-min
darkroom incubation in 3% H2O2-methanol. For antigen
processing, sections were rehydrated and treated with
10 mmol/l citrate acid at 80°C for 10 min. After three
changes of distilled water, sections were then treated with
10% normal goat serum for 40 min and incubated in
antinitrotyrosine antibody (1:1000 dilution; Upstate Bio-
technology, Lake Placid, New York) solution overnight.
The next day, tissue sections were rinsed with phosphate-
buffered saline three times (5 min each) and processed for
demonstration of immunoreactive protein with an immu-
noenzymatic staining kit (DAKO, Carpinteria, California)
and an Immunopure Metal Enhanced diaminobenzidine
substrate (Pierce, Rockford, Illinois) as directed by the
manufacturers. The presence of immunoreactive protein
was assessed microscopically by an independent reviewer.
Statistical analysis. The effect of L-NNA on percent
change of Ascz2 and fractional area was tested using a
repeated measures analysis. The two factors in the analysis
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of Ascz2 were treatment (L-NNA and saline) and time (1 to
10 min). For fractional area, the two factors were treatment
and condition (preocclusion, occlusion, and reperfusion).
For each of these variables, mean contrasts and correspond-
ing t test statistics were computed for the pairwise compar-
isons of interest based on estimates of mean differences and
SE from the repeated measures analysis. Bonferroni’s
method was applied to adjust for the multiple number of
statistical tests performed. A Bonferroni-adjusted p value
,0.05 was considered statistically significant. The statistical
analysis was done using the SAS/STAT procedure MIXED
(23).
A repeated measures analysis was used to compare myo-
cardial blood flow among three conditions (baseline, occlu-
sion and reperfusion) for control and L-NNA dogs and also
between control and L-NNA groups for all three conditions.
The factors included in the repeated measures analysis were
treatment (control vs. L-NNA) and condition (baseline,
occlusion and reperfusion). Bonferroni’s method was ap-
plied to the p values to adjust for the number of tests
performed. A Bonferroni-adjusted p ,0.05 was considered
statistically significant.
RESULTS
Changes in coronary venous Ascz2 concentration during
ischemia-reperfusion in the control dogs and the L-NNA
dogs are summarized in Figure 1 and Table 1. The
prereperfusion Ascz2 concentrations were similar in the
control (saline) dogs and the L-NNA dogs, 3.2 6 0.5
nmol/liter and 3.2 6 0.9 nmol/liter, respectively. In the
control dogs the Ascz2 concentration rose 50% to 4.8 6 1.1
nmol/liter. In comparison, Ascz2 concentration in the
L-NNA dogs rose to 3.7 6 1.3 nmol/liter, a 25% rise (p ,
0.01 vs. control dogs at 4 min reperfusion) (Fig. 1).
Compared to the baseline value, only the 1-, 2- and 3-min
Ascz2 concentrations in the L-NNA dogs showed signifi-
cant increases after reperfusion, whereas in the control dogs
the Ascz2 increases were significant throughout the first
6 min after reperfusion compared to baseline. The area
under the curve of percent change in Ascz2 signal was 107
(arbitrary units) for the control dogs versus 52 for the
L-NNA dogs, a 52% decrease in area. The arterial concen-
trations of Ascz2 were similar in the L-NNA dogs and the
Figure 1. Coronary sinus concentration of ascorbate free radical (Ascz2)
after ischemia-reperfusion sequences. The rise in Ascz2 concentration is
significantly lower in the animals receiving the nitric oxide synthase
inhibitor NG-nitro-L-arginine (L-NNA).
Table 1. Ascorbate Free Radical Data (nmol/l)
Dog no. Baseline 1 min 2 min 3 min 4 min 5 min 6 min 7 min 8 min 9 min 10 min
Saline Animals
1 3.96 4.55 5.65 5.65 5.95 6.31 6.31 6.46 6.46 6.24 6.31
2 2.68 3.82 4.11 4.03 4.03 3.96 3.38 3.38 3.45 3.16 3.16
3 2.86 3.82 4.26 4.11 4.11 4.11 3.74 3.52 3.52 3.30 3.60
4 3.01 3.96 3.52 3.74 3.74 3.60 3.23 3.23 2.94 2.79 2.79
5 3.30 3.67 3.67 3.96 6.02 5.21 5.21 4.70 3.82 3.52 3.67
Mean 3.16 3.96 4.24 4.30 4.77 4.64 4.37 4.26 4.04 3.80 3.91
SD 0.50 0.34 0.84 0.77 1.11 1.11 1.34 1.36 1.39 1.39 1.39
L-NNA Animals
1 1.61 1.61 1.76 1.76 1.47 1.39 1.54 1.61 1.76 1.61 1.61
2 4.44 4.92 4.84 4.62 4.62 4.55 4.55 4.70 4.70 4.70 4.92
3 3.82 4.04 3.23 3.52 3.52 3.60 3.67 3.67 3.30 3.82 3.67
4 4.18 4.84 5.36 5.21 5.28 5.28 5.28 4.70 4.70 4.84 4.84
5 3.34 5.58 5.58 5.58 5.43 5.43 4.92 4.92 4.70 3.67 3.67
6 3.01 3.74 4.04 3.89 3.30 3.30 3.45 3.52 3.45 3.45 3.89
7 2.97 3.93 3.93 3.60 3.60 3.60 3.67 3.45 3.08 3.16 3.16
8 3.08 4.18 4.18 4.18 3.67 3.23 3.23 3.52 3.16 3.16 3.23
9 2.31 2.86 2.94 2.94 2.57 3.45 2.64 2.79 2.28 2.50 2.35
Mean 3.20 3.97 3.98 3.92 3.72 3.76 3.66 3.65 3.46 3.43 3.48
SD 0.89 1.18 1.22 1.17 1.26 1.22 1.16 1.05 1.07 1.01 1.07
Times are minutes after reperfusion.
L-NNA 5 NG-nitro-L-arginine.
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control dogs just prior to reperfusion, (6.8 6 2.0 nmol/liter
vs. 8.1 6 1.4 nmol/liter, respectively, p 5 NS) and showed
no significant change during reperfusion.
Echocardiographic-measured fractional area shortening
is shown in Figure 2. The control (saline) dogs showed a
decline in fractional area shortening from 38 6 19% to 26 6
14% (p 5 0.01 vs. baseline) during ischemia, and a further
decline to 22 6 11% (p , 0.001 vs. baseline) after
reperfusion. In the L-NNA dogs the fractional area short-
ening was 36 6 13% at baseline, fell to 27 6 12% (p , 0.01)
during ischemia, but then rose to 33 6 14% (p 5 NS vs.
baseline) postreperfusion. Intraobserver and interobserver
variability correlations by regression analysis were y 5
0.88x 1 0.92; r 5 0.97 and y 5 0.93x 1 3.09; r 5 0.98,
respectively.
The hemodynamic data are summarized in Table 2. None
of the differences were statistically significant.
Changes in myocardial blood flow during ischemia-
reperfusion for control and L-NNA–treated groups are
summarized in Table 3. For the control (no L-NNA) dogs,
myocardial perfusion during occlusion was significantly
(p , 0.01) lower than during baseline, and it returned to
baseline level during reperfusion. For the L-NNA–treated
dogs, the pattern was similar: myocardial perfusion during
occlusion fell from baseline and returned to baseline level
with reperfusion. Furthermore, the repeated-measures anal-
ysis also demonstrated no differences in myocardial perfu-
sion during baseline, occlusion and reperfusion between the
control and L-NNA groups (p 5 NS for all three condi-
tions).
The coronary risk areas stained by Evans blue dye were
similar in the two groups of animals: 30.6 6 6.6% (control)
versus 32.0 6 7.2% (L-NNA), p 5 NS.
Representative sections of the immunohistochemistry
staining are shown in Figures 3, 4 and 5. In the absence of
the antinitrotyrosine antibody, no nitrotyrosine is demon-
strated (Fig. 3). Figure 4 shows a large quantity of nitro-
tyrosine (brown stain in cytoplasm) is present in myocar-
dium subjected to an occlusion-reperfusion sequence
without L-NNA. Myocardium from the nonischemic region
indicated minimal nitrotyrosine (not shown). Figure 5
shows myocardium from dogs receiving L-NNA during
the occlusion-reperfusion sequence; only minimum nitro-
tyrosine is present.
DISCUSSION
The major findings of this study are: 1) L-NNA decreases
coronary sinus free radical concentration and tissue per-
oxynitrite formation in an ischemia-reperfusion canine
model, and 2) the decrease in free radical concentration is
accompanied by less postreperfusion myocardial stunning as
measured by fractional area shortening with transthoracic
echocardiography.
Previous studies of NO synthase inhibitors in ischemia-
reperfusion injury. Numerous other studies have impli-
cated the nitric oxide-peroxynitrite pathway in ischemia-
reperfusion injury (24–41). Various competitive inhibitors
of the NOS enzyme have been shown to reduce reperfusion
injury in various settings. Patel et al. (25), in open-chest
rabbits, showed that L-NAME reduced myocardial infarct
size after 30 to 60 min of regional ischemia. Wang and
Zweier (26) observed that L-NAME inhibited NO gener-
Figure 2. Fractional area shortening by echocardiography after ischemia
and reperfusion. A significant decline in fractional area shortening by
echocardiography occurs during ischemia in both animal groups. In
animals receiving saline a further decline in fractional area shortening
(FAS) is seen after reperfusion, indicating “stunning”; in the NG-nitro-L-
arginine (L-NNA) animals, FAS after reperfusion returns to baseline
levels—a cardioprotective effect.
Table 2. Hemodynamic Data
Systolic Arterial
Pressure
(mm Hg)
Diastolic Arterial
Pressure
(mm Hg)
Heart Rate
(beats/min)
Saline L-NNA Saline L-NNA Saline L-NNA
Baseline 133 6 12 124 6 44 97 6 7 83 6 24 99 6 11 103 6 21
Ischemia 110 6 15 112 6 38 83 6 15 72 6 25 118 6 17 108 6 18
Reperfusion 117 6 15 116 6 28 86 6 13 79 6 24 99 6 21 99 6 18
Data are mean 6 SD.
L-NNA 5 NG-nitro-L-arginine.
Table 3. Myocardial Perfusion
Group Baseline Occlusion Reperfusion
Control (n 5 5) 0.52 6 0.11 0.07 6 0.03* 0.50 6 0.12†
L-NNA (n 5 6) 0.47 6 0.05 0.08 6 0.03* 0.40 6 0.06†
*p , 0.01 vs. baseline for control and L-NNA dogs; †p , 0.05 vs. occlusion for
control and L-NNA dogs. Mean 6 SE, myocardial perfusion: ml/min/g.
L-NNA 5 NG-nitro-L-arginine.
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ation by over 80% and tripled the recovery of contractile
function in isolated perfused rat hearts subjected to 30 min
of global ischemia. A similar result was found by Naseem et
al. (27), who used the NO synthase inhibitor L-NNA.
Morita et al. (28) studied piglets rendered hypoxic while on
cardiopulmonary bypass, and again showed that L-NAME
had beneficial effects on recovery of left ventricular function.
Xie and Wolin (30) demonstrated that reoxygenation-
induced inhibition of cardiac muscle mitochondrial respira-
tion was blocked by NO synthase inhibitors. Flogel et al.
(31), using endothelial NO synthase knockout mice, found
that endogeneously formed NO contributed to ischemia-
reperfusion injury in the saline-perfused isolated mouse
heart, most likely by peroxynitrite formation. Mori et al.
(32) showed that intracoronary administration of L-arginine
in dogs aggravated myocardial stunning through production
of peroxynitrite; L-NAME improved myocardial contractile
function in the ischemic region.
In contrast to the above studies, Engleman et al. (33) in
an isolated working rat heart model found the NO precursor
arginine ameliorated the endothelial dysfunction resulting
from global ischemia-reperfusion sequences. A series of
studies from Lefer’s group found NO and peroxynitrite to
be cardioprotective: after 5.5 h of ischemia-reperfusion in an
open-chest dog model (34), in the isolated perfused rat
heart undergoing global ischemia-reperfusion (35), and
when peroxynitrite was administered directly into the left
ventricle of open-chest cats during 90 min of ischemia and
4.5 h of reperfusion (36). In the latter study the adminis-
tration of IV peroxynitrite was not cardioprotective. The
cardioprotective effects of peroxynitrite may result from
attenuation of polymorphonuclear leukocyte rolling and
from adhesion to the coronary endothelium (32,37), al-
though we found this mechanism did not reduce postisch-
emic myocardial stunning (38). Hasebe et al. (39) found a
deleterious effect of the NO synthase inhibitor L-NNA.
Their study utilized a postthoracotomy canine model; the
animals were subjected to three coronary occlusions (10 min
each), and the L-NNA was administered intracoronary, not
IV. The L-NNA caused a slower return of regional function
(implanted sonomicrometers) compared to controls, al-
though function did ultimately return to baseline. Jones et
al. (40) showed a protective role of NO in the late phase of
ischemic preconditioning in the conscious rabbit model.
Kudejl et al. (41) showed adverse effects of NO inhibition in
the conscious pig with coronary stenosis, whereas Gotto et
al. (42) noted that L-NAME pretreatment did not affect
protection of ischemic myocardium by ischemic precondi-
tioning.
Thus, NO may have dual effects, beneficial in preserving
endothelial function, preventing leukocyte adhesion, and
promoting vasodilation, although harmful because it com-
bines with superoxide after occlusion-reperfusion sequences
to generate toxic peroxynitrite. The difference in results
Figure 3. Representative photomicrograph of myocardium subjected to an
occlusion-reperfusion sequence without receiving NG-nitro-L-arginine
and stained as described (see text), but not incubated in antinitrotyrosine
antibody. No nitrotyrosine is demonstrated. Compare to Figure 4.
Figure 4. Representative photomicrograph of myocardium subjected to a
coronary occlusion-reperfusion sequence and incubated with antinitroty-
rosine antibody. Heavy nitrotyrosine staining of the cytoplasm (brown
stain) is evident. Compare to Figure 3. This dog did not receive the nitric
oxide synthase inhibitor NG-nitro-L-arginine.
Figure 5. Representative photomicrograph of myocardium subjected to an
occlusion-reperfusion sequence and incubated with antinitrotyrosine anti-
body. This dog received the nitricoxide synthase inhibitor NG-nitro-L-
arginine during the occlusion-reperfusion sequence. Only minimal nitro-
tyrosine staining is present. Compare to Figure 4.
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from the various studies discussed above may be due to the
experimental models. Many of these studies have been done
in isolated perfused rat hearts, often with prolonged isch-
emia resulting in irreversible necrosis and infarction, rather
than potentially reversible postischemic dysfunction or stun-
ning. We are unaware of any study in a closed-chest canine
ischemia-reperfusion model that has evaluated simulta-
neously the effect of NO synthase inhibitors on free radical
concentration and myocardial contractility.
Advantages of the ascorbate free radical technique. Im-
portant previous investigations have used spin-trapping
techniques to demonstrate free radical generation in isch-
emia-reperfusion injury (43–45). Although valuable infor-
mation has been gained, the spintrapping technique has
some limitations. Spin traps when given intracoronary or at
high concentrations systemically have significant cardiac
effects (46). The spin-trap technique cannot provide on-line
analysis of free radical concentration, as our ascorbate free
radical technique allows. Also, during the processing of
samples containing spin adducts, chain reactions cannot
always be prevented, including lipid peroxidation.
Electron paramagnetic resonance using the ascorbate free
radical technique allows immediate quantitative determina-
tion of free radical concentration. Previous studies in our
laboratory have demonstrated that Ascz2 rises reproducibly
after an ischemia-reperfusion sequence (20,47). The rise in
Ascz2 elevation has been shown to be greatest after 20 min
of occlusion (47). In the absence of ischemia, Ascz2 con-
centration over time has been demonstrated to be stable
(20). The Ascz2 concentration is not altered by changes in
coronary flow. Although ascorbate itself is an antioxidant,
we have shown that exogenous ascorbate, administered as
we did, does not alter or attenuate myocardial stunning (20).
There is no known direct interaction between NO and
ascorbate. Thus, the ascorbate EPR method is a unique,
robust, real-time method of monitoring free radical stress
(total oxidative stress) in a whole animal model (17–20).
A disadvantage of the ascorbate radical technique is that
it cannot measure the concentration of other individual
radicals such as the O2
z2 and HOz2; however, it yields
information on total oxidative flux.
Myocardial perfusion. To assess the effect of L-NNA
on regional myocardial perfusion during ischemia-
reperfusion sequence, we measured myocardial perfusion
in 11 dogs using a new isotope-labeled microsphere
method, namely a neutron activation assay (21). Traditional
methods for measuring myocardial blood flow, such as
radiolabeled microspheres, which have been extensively
employed, have some disadvantages: expensive, radioactive
and time-consuming. The new neutron activation assay
microsphere technique is an analytic method whereby neu-
trons penetrate the sample and activate elements within the
sample (48,49). Reinhardt et al. (21) recently compared this
technique with traditional radiolabeled microsphere method
in an in vivo rabbit model of myocardial ischemia and
reperfusion and demonstrated a linear relationship of myo-
cardial blood flow measurements between the two methods
over a wide detection range. Our present study showed that
for both control and L-NNA–treated groups, risk area
myocardial perfusion fell significantly during coronary oc-
clusion and returned to baseline level during reperfusion.
Importantly, L-NNA did not alter myocardial blood flow
during the ischemia and reperfusion sequences compared to
the control non-L-NNA dogs. This result rules out the
possibility that differences in myocardial perfusion could be
the cause of differences in ascorbate free radical production
and contractile dysfunction between the groups. A similar
conclusion was reached by Araki et al. (50), who used the
colored microsphere technique to show that L-NAME did
not alter regional myocardial perfusion in a porcine model of
ischemia-reperfusion.
Study limitations. Anesthesia is known to depress left
ventricular function, and it probably added to the cardiode-
pressant effect of the ischemia-reperfusion sequences. The
dogs in the control and L-NNA groups were both given the
same anesthetics.
Coronary artery occlusion in this study was limited to
only 20 min, an interval known to produce stunning, but not
infarction. Thus, our conclusions are only applicable to a
20-min (stunning) preparation. Shorter or longer coronary
occlusion intervals might change the results. We have
previously demonstrated that longer durations of coronary
occlusion, .20 min (i.e., producing infarction), yielded
smaller percentage increases in Ascz2 after reperfusion (47).
During baseline and reperfusion, the myocardial blood
flows we measured using the neutron activation microsphere
assay method were lower than measurements we have
previously made using traditional radiolabeled microspheres
(51). These differences from our earlier study may be due to
the use of a different perfusion measurement method, and
differences in anesthetics. Despite these differences, the
decline in perfusion during occlusion and recovery during
reperfusion followed the expected pattern and was not
altered by L-NNA.
The dose of L-NNA we selected was arbitrary, and a
dose-response study was not attempted. Higher doses of
L-NNA might have different effects on free radical concen-
tration after ischemia-reperfusion sequences.
Unlike L-NAME, L-NNA (used in our study) does not
appear to inhibit the superoxide generated with uncoupling
of endothelial nitric oxide synthase (52,53). However, we
have not excluded the possibility that L-NNA may also
decrease superoxide production.
Conclusions. Free radicals are generated from reperfusion
injury, and free radicals are known to be toxic to the
myocardium. Peroxynitrite, a product of NO and superox-
ide, is toxic, unstable, highly reactive and causes lipid
peroxidation. We have demonstrated that by inhibiting NO
production with an NOS inhibitor (L-NNA) during a
myocardial ischemia-reperfusion sequence, coronary sinus
free radical concentration was significantly diminished, and
accumulation of the peroxynitration product nitrotyrosine was
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reduced. The expected decrease in left ventricular fractional
shortening was abolished, indicating protection against myo-
cardial stunning. The NOS inhibitors deserve further evalua-
tion as cardioprotective agents against reperfusion injury.
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